Abstract
Purpose
Several clinical phenotypes including fetal hydrops, central conducting lymphatic anomaly or capillary malformations with arteriovenous malformations 2 (CM-AVM2) have been associated with EPHB4 (Ephrin type B receptor 4) variants, demanding new approaches for deciphering pathogenesis of novel variants of uncertain significance (VUS) identified in EPHB4, and for the identification of differentiated disease mechanisms at the molecular level.
Methods
Ten index cases with various phenotypes, either fetal hydrops, CM-AVM2, or peripheral lower limb lymphedema, whose distinct clinical phenotypes are described in detail in this study, presented with a variant in EPHB4. In vitro functional studies were performed to confirm pathogenicity.
Results
Pathogenicity was demonstrated for six of the seven novel EPHB4 VUS investigated. A heterogeneity of molecular disease mechanisms was identified, from loss of protein production or aberrant subcellular localization to total reduction of the phosphorylation capability of the receptor. There was some phenotype–genotype correlation; however, previously unreported intrafamilial overlapping phenotypes such as lymphatic-related fetal hydrops (LRFH) and CM-AVM2 in the same family were observed.
Conclusion
This study highlights the usefulness of protein expression and subcellular localization studies to predict EPHB4 variant pathogenesis. Our accurate clinical phenotyping expands our interpretation of the Janus-faced spectrum of EPHB4-related disorders, introducing the discovery of cases with overlapping phenotypes.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details





















1 St George’s University of London, Molecular and Clinical Sciences Institute, London, UK (GRID:grid.264200.2) (ISNI:0000 0000 8546 682X)
2 Haukeland University Hospital, Department of Obstetrics and Gynecology, Bergen, Norway (GRID:grid.412008.f) (ISNI:0000 0000 9753 1393)
3 Wellcome Sanger Institute, Hinxton, UK (GRID:grid.10306.34) (ISNI:0000 0004 0606 5382)
4 North Thames Genomic Laboratory Hub, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK (GRID:grid.424537.3) (ISNI:0000 0004 5902 9895); UCL Great Ormond Street Institute of Child Health, Genetics and Genomic Medicine, London, UK (GRID:grid.83440.3b) (ISNI:0000000121901201)
5 University Medical Center Hamburg Eppendorf, Institute of Human Genetics, Hamburg, Germany (GRID:grid.13648.38) (ISNI:0000 0001 2180 3484)
6 Departments of Pediatrics – Section of Genetics and Child Development, Dartmouth-Hitchcock Medical Center, Lebanon, USA (GRID:grid.413480.a) (ISNI:0000 0004 0440 749X); Geisel School of Medicine at Dartmouth College, Hanover, USA (GRID:grid.254880.3) (ISNI:0000 0001 2179 2404)
7 University of Missouri School of Medicine, Department of Child Health, Columbia, USA (GRID:grid.134936.a) (ISNI:0000 0001 2162 3504)
8 GeneDx, 207 Perry Parkway, Gaithersburg, USA (GRID:grid.428467.b)
9 St George’s University of London, Molecular and Clinical Sciences Institute, London, UK (GRID:grid.264200.2) (ISNI:0000 0000 8546 682X); University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom (GRID:grid.410421.2) (ISNI:0000 0004 0380 7336)
10 Haukeland University Hospital, Neonatal intensive care unit, Children’s Department, Bergen, Norway (GRID:grid.412008.f) (ISNI:0000 0000 9753 1393)
11 Haukeland University Hospital, Department of Medical Genetics, Bergen, Norway (GRID:grid.412008.f) (ISNI:0000 0000 9753 1393)
12 Department of Neonatology and Paediatric Intensive Care, Altona Children’s Hospital, Hamburg, Germany (GRID:grid.440279.c) (ISNI:0000 0004 0393 823X)
13 Elbe Center for Prenatal Medicine, Hamburg, Germany (GRID:grid.440279.c)
14 St George’s University of London, Molecular and Clinical Sciences Institute, London, UK (GRID:grid.264200.2) (ISNI:0000 0000 8546 682X); St George’s Universities NHS Foundation Trust, Dermatology & Lymphovascular Medicine, London, UK (GRID:grid.264200.2) (ISNI:0000 0000 8546 682X)
15 St George’s University of London, Molecular and Clinical Sciences Institute, London, UK (GRID:grid.264200.2) (ISNI:0000 0000 8546 682X); South West Thames Regional Genetics Service, St George’s NHS Foundation Trust, London, UK (GRID:grid.451052.7) (ISNI:0000 0004 0581 2008)
16 North Thames Genomic Laboratory Hub, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK (GRID:grid.424537.3) (ISNI:0000 0004 5902 9895)
17 University of Birmingham, The Institute of Metabolism & Systems Research, College of Medical & Dental Sciences, Birmingham, UK (GRID:grid.6572.6) (ISNI:0000 0004 1936 7486); West Midlands Fetal Medicine Centre, Birmingham Women’s & Children’s Foundation Trust, Birmingham, UK (GRID:grid.6572.6)
18 Departments of Pediatrics – Section of Genetics and Child Development, Dartmouth-Hitchcock Medical Center, Lebanon, USA (GRID:grid.413480.a) (ISNI:0000 0004 0440 749X)